PBE Performance — Invesco Biotechnology & Genome ETF
Data updated: 2026-09-28
PBE returned +10.18% year to date and +39.59% over one year to Jul 2026. Annualised returns are +12.98% over 3 years and +3.95% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $144, against $137 for the category, and to $140 over one year, against $137. Volatility over the past three years was 17.31% a year. In the 12 months to Jul 2026 the fund lost a net $16.8M, and assets reached $281.95M.
PBE Growth of $100
What $100 invested in Invesco Biotechnology & Genome ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | PBE | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $140 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $144 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $121 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $173 | $183 |
PBE Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +10.18% |
| 1 year | +39.59% |
| 3 years (annualised) | +12.98% |
| 5 years (annualised) | +3.95% |
PBE Annual Returns
Calendar-year total returns of Invesco Biotechnology & Genome ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +10.18% |
| 2025 | +24.72% |
| 2024 | +1.09% |
| 2023 | +3.67% |
| 2022 | −10.77% |
| 2021 | +1.56% |
| 2020 | +25.51% |
| 2019 (Aug–Dec) | +5.65% |
PBE Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.2% | +0.1% | −3.3% | +0.4% | +5.4% | +8.0% | −0.2% | — | — | — | — | — |
| 2025 | +4.2% | −3.7% | −4.8% | −1.9% | +0.6% | +2.5% | +1.9% | +4.8% | +2.3% | +7.2% | +11.5% | −1.0% |
| 2024 | −2.5% | +2.0% | −1.2% | −6.0% | +4.1% | +2.4% | +8.1% | +2.5% | −2.8% | −2.4% | +3.3% | −5.6% |
| 2023 | +5.2% | −4.8% | −1.3% | −0.3% | −3.6% | +1.5% | +3.6% | −3.1% | −7.2% | −6.1% | +9.3% | +12.4% |
| 2022 | −14.6% | −0.9% | +2.8% | −9.3% | +1.1% | +1.6% | +5.5% | −1.0% | −2.6% | +7.6% | +5.3% | −4.7% |
| 2021 | +7.7% | −1.8% | −0.6% | +2.1% | −2.8% | +5.7% | −2.5% | +4.0% | −4.7% | +0.3% | −6.1% | +1.1% |
| 2020 | −3.4% | −6.9% | −7.4% | +14.3% | +9.3% | +0.2% | +1.2% | −0.6% | −3.4% | +0.1% | +12.8% | +9.7% |
| 2019 | — | — | — | — | — | — | — | −5.5% | −5.2% | +7.7% | +8.3% | +1.1% |
PBE Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 17.31%
- 3-year Sharpe ratio: 0.49 (vs 4.5% risk-free rate)
- Best month: +12.39% (Dec 2023)
- Worst month: −7.19% (Sep 2023)
PBE Fund Flows
Monthly money in and out of Invesco Biotechnology & Genome ETF, from SEC Form N-PORT.
- 12-month net flow: −$16.8M
- 12-month gross sales (incl. reinvestments): $73.0M
- Sales ÷ redemptions: 0.81×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $4.6M | $0 | $4.6M |
| Jun 2026 | $57.1M | $54.2M | $2.9M |
| May 2026 | $0 | $1.6M | −$1.6M |
| Apr 2026 | $2.4M | $2.4M | $18K |
| Mar 2026 | $0 | $5.4M | −$5.4M |
| Feb 2026 | $0 | $2.5M | −$2.5M |
| Jan 2026 | $4.2M | $0 | $4.2M |
| Dec 2025 | $834K | $0 | $834K |
| Nov 2025 | $3.2M | $1.6M | $1.7M |
| Oct 2025 | $0 | $722K | −$722K |
| Sep 2025 | $0 | $3.5M | −$3.5M |
| Aug 2025 | $676K | $17.9M | −$17.3M |
PBE Assets Under Management
Net assets of Invesco Biotechnology & Genome ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $281.95M |
| 2026-04-30 | $247.38M |
| 2026-01-31 | $262.98M |
| 2025-10-31 | $234.12M |
| 2025-07-31 | $225.44M |
| 2025-04-30 | $221.28M |
| 2025-01-31 | $255.16M |
| 2024-10-31 | $257.12M |
| 2024-07-31 | $269.88M |
| 2024-04-30 | $245.81M |
| 2024-01-31 | $256.19M |
| 2023-10-31 | $210.65M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.